QUOTE AND NEWS
FiercePharma  Apr 10  Comment 
A strong regulatory agency and the patient confidence it inspires are essential for both patients and the industry as a whole, Sanofi CEO Chris Viehbacher said Thursday. And while the FDA has made recent strides in restoring the patient trust the...
FiercePharma  Apr 10  Comment 
With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.
FierceBiotech  Apr 9  Comment 
Three years ago, Sanofi walked away from a $375 million diabetes partnership with Metabolex, which had just salved the wound with a new pact with J&J. Now, operating under a new name--CymaBay--and armed with a fresh $38 million raise from late...
Benzinga  Apr 8  Comment 
Below are the top drug manufacturers-major stocks on the NYSE in terms of dividend yield. AstraZeneca PLC (NYSE: AZN) has a dividend yield of 5.90%. AstraZeneca's shares closed at $64.05 yesterday. GlaxoSmithKline plc (NYSE: GSK) has a...
FiercePharma  Apr 7  Comment 
Sanofi investors are fed up with disappointing news on the multiple sclerosis drug Lemtrada. Vaunted as a potential blockbuster, the drug hasn't even made it to market in the U.S. Now, some investment funds are suing the French drugmaker, saying...
FierceBiotech  Apr 7  Comment 
Sanofi is walking away from any plans to appeal the FDA's emphatic rejection of the multiple sclerosis drug Lemtrada, at least for now. But rather than launching the added trial that the FDA demanded ahead of any possible approval, the company...
StreetInsider.com  Apr 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi%27s+%28SNY%29+Genzyme+Will+Resubmit+Alemtuzumab+sBLA+as+MS+Treatment/9356364.html for the full story.
newratings.com  Apr 7  Comment 
PARIS (dpa-AFX) - After constructive talks with the U.S. Food and Drug Administration or FDA, Sanofi's unit, Genzyme, plans to resubmit in the second quarter its supplemental Biologics License Application or sBLA seeking approval of Lemtrada...
FierceBiotech  Apr 3  Comment 
A few days after a similar announcement from GlaxoSmithKline, Sanofi said it plans to scale up its presence in Africa, looking to invest in marketing and R&D in response to the market's continued growth.
Reuters  Apr 2  Comment 
Sanofi is on the lookout for acquisitions to boost key business units, such as consumer and animal health products, and expects strong growth in the "strategic continent" of Africa, its chief executive told Reuters on Wednesday.




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki